Leading developer and marketer of innovative surgical solutions for peripheral nerve injuries
AxoGen (Nasdaq: AXGN) has a portfolio of regenerative medicine products focused on peripheral nerve repair with its market-leading Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with an additional surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachment.
AxoGen is changing the treatment paradigm for peripheral nerve injuries, moving surgeons away from the traditional nerve autograft harvest technique that requires an additional surgical site which may result in a loss of feeling where the autograft nerve was removed, potential pain at the donor site, or other known donor site morbidities to the use of Avance® Nerve Graft. Peripheral nerve repair with Avance® Nerve Graft does not require autograft nerve tissue harvest, thus avoiding the associated complications, comorbidities and expenses associated with the harvest procedure.
AxoGen is headquartered in Alachua, Florida and sells its products globally, generating LTM sales of ~$21M at the time of our investment.
- In 2015, Essex Woodlands acquired publicly traded shares of AxoGen by investing primary capital to accelerate the company's growth trajectory